Catalent to strengthen cell and gene offering with MaSTherCell acquisition

10 Feb 2020

Catalent has further strengthened its cell and gene offering by agreeing to buy MaSTherCell, a Belgium-based contract development and manufacturing organisation for USD315 million.

MaSTherCell – currently owned by healthcare investment firm Great Point Partners and biopharmaceutical company Orgenesis -- has a portfolio of autologous and allogeneic cell therapies, including some based on chimeric antibody receptor-engineered T cells (CAR-T), T cell receptors (TCR), tumor-infiltrating lymphocytes (TIL) and mesenchymak stem cells (MSC).

Catalent to strengthen cell and gene offering with MaSTherCell acquisition

It has a 25,000 square-foot facility in Gosselies, Belgium and a 32,000 square-foot US plant in Houston.

It is also currently building a dedicated 60,000 square-foot commercial-scale production and fill-finish facility at Gosselies, which is scheduled to open in the autumn of 2021.

“MaSTherCell extends our leadership position in the biotech industry, complements our leading gene therapy offering, and allows us to deliver comprehensive development, manufacturing, analytical, fill-finish, and clinical supply solutions for innovators across the large molecule space,” said John Chiminski, Chief Executive Officer at Catalent.

On completion of the deal – which is expected to close in the third quarter of Catalent’s 2020 fiscal year – MaSTherCell will become part of the Catalent Biologics business.